References
- American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. DSM-IV. Washington, DC, American Psychiatric Association.
- Bubl E, Perlov E, Tebartz VEL. Aripiprazole in Patients with Tourette syndrome. World J Biol Psychiatry 2006; 7: 123–125
- Butler IJ, Koslow SH, Seifert WEJr, Caprioli RM, Singer HS. Biogenic amine metabolism in Tourette syndrome. Ann Neurol 1979; 6: 37–39
- Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006; 21: 447–453
- Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 86–94
- Jankovic J. Tourette's syndrome. N Engl J Med 2001; 345: 1184–1192
- Kastrup A, Schlotter W, Plewnia C, Bartles M. Treatment of tics in Tourette's syndrome with aripiprazole. J Clin Psychopharmacol 2005; 25: 94–96
- Kawohl, W, Schneider, F, Vernaleken, I, Neuner, I. 2008. Aripiprazole in the treatment of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry, in press.
- Kirschbaum KM, Muller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2007; 11: 1–7
- Leckman JF. Tourette's syndrome. Lancet 2002; 360: 1577–1586
- Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KI, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28: 566–573
- Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995; 12: 73–86
- Murphy TK, Bengston MA, Soto O, Edge PJ, Sajid MW, Shapira N, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005; 8: 489–490
- Singer HS, Butler IJ, Tune LE, Seifert WE, Jr, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 1982a; 12: 361–366
- Singer HS, Tune LE, Butler IJ, Zaczek R, Coyle JT. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome. Adv Neurol 1982b; 35: 177–183
- Tijssen MAJ, Brown P, Morris HR, Lee A. Late onset startle induced tics. J Neurol Neurosurg Psychiatry 1999; 67: 782–784
- Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 2006; 60: 389–393
- Yoshimura, R, Ueda, N, Hori, H, Ikenouchi-Sugita, A, Umene-Nakano, W, Nakamura, J. 2008. Differential patterns of longitudinally changes in plasma levels of catecholamine and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenia patients. World J Biol Psychiatry, in press.